La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Altimmune Dividendo

Dividendo criteri di controllo 0/6

Altimmune non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore	2.0%
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Utile per azione	-US$1.43
Previsione del rendimento del dividendo a 3 anni	n/a

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Jun 24

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Feb 27

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Feb 12

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

Feb 10

Thoroughly Derisked, Altimmune Is Now A Great Buy

Jan 10

Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

Oct 11

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Jun 27

Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

Feb 12

We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Oct 27

Altimmune: Overreaction On NASH Data Creates Buying Opportunity

Sep 15

Reassessing Altimmune

Sep 07

Altimmune sets new 52-week high on rising volume

Aug 31

Altimmune Q2 2022 Earnings Preview

Aug 10

Altimmune: Several Catalysts In 2 Large Market Indications This Year

Jun 29

Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Jun 27

Altimmune's New Avatar As A Liver Disease Player

Apr 07

Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Feb 01

Altimmune: Changing Focus To Pemvidutide In 2022

Jan 03

Altimmune: Changing The Thesis

Oct 16

Here's Why Altimmune, Inc.'s (NASDAQ:ALT) CEO Compensation Is The Least Of Shareholders Concerns

Sep 17

We're Hopeful That Altimmune (NASDAQ:ALT) Will Use Its Cash Wisely

Aug 06

Altimmune: NASH And Obesity At The End Of The COVID Tunnel

Jul 27

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di ALT siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di ALT siano aumentati.

Rendimento dei dividendi rispetto al mercato

Altimmune Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di ALT rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (ALT)	n/a
Fondo del 25% del mercato (US)	1.4%
Top 25% del mercato (US)	4.5%
Media del settore (Biotechs)	2.0%
Previsione dell'analista in 3 anni (ALT)	n/a

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di ALT rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di ALT rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di ALT per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché ALT non ha segnalato alcun pagamento.

Altimmune Dividendo

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sui dividendi

Recent updates

Altimmune, Inc., Annual General Meeting, Sep 26, 2024

Altimmune, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Altimmune, Inc. Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology

Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Altimmune, Inc. Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity at the American Diabetes Association’s 84th Scientific Sessions

Altimmune, Inc. Presents Data at EASL International Liver Congress™? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)

Pomerantz LLP Announces Filing of Class Action Against Altimmune, Inc. and Certain Officers

Altimmune, Inc. to Report Q1, 2024 Results on May 09, 2024

Buy Altimmune's Potential Market Disruption With Pemvidutide

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023

Altimmune, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

President exercised options and sold US$115k worth of stock

Thoroughly Derisked, Altimmune Is Now A Great Buy

Price target increased by 11% to US$21.29

Altimmune, Inc. Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Altimmune, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Altimmune, Inc. Grants Fast Track Designation by FDA for Pemvidutide for the Treatment of Non Alcoholic Steatohepatitis (Nash)

Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

Consensus revenue estimates decrease by 29%

Altimmune, Inc., Annual General Meeting, Sep 28, 2023

Consensus revenue estimates increase by 11%

Price target decreased by 21% to US$19.38

Altimmune, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Altimmune, Inc. Announces Initiation of Phase 2b Impact Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Al Alcoholic Steatohepatitis

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Price target decreased by 11% to US$26.25

Altimmune, Inc. to Report Q1, 2023 Results on May 11, 2023

Price target decreased by 11% to US$26.25

Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

President exercised options and sold US$106k worth of stock

Altimmune, Inc. Appoints Raymond Jordt as Chief Business Officer

Independent Director exercised options and sold US$248k worth of stock

Altimmune, Inc. Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease

Consensus forecasts updated

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Altimmune, Inc. to Report Q3, 2022 Results on Nov 10, 2022

We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Altimmune, Inc. Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight

Altimmune, Inc. Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD

Altimmune: Overreaction On NASH Data Creates Buying Opportunity

Reassessing Altimmune

Altimmune sets new 52-week high on rising volume

Consensus forecasts updated

Altimmune, Inc., Annual General Meeting, Sep 29, 2022

Price target increased to US$24.86

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Altimmune Q2 2022 Earnings Preview

Altimmune, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Chief Scientific Officer exercised options and sold US$369k worth of stock

Altimmune: Several Catalysts In 2 Large Market Indications This Year

Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Independent Director recently bought US$5.4k worth of stock

Consensus forecasts updated

Price target decreased to US$24.43

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Altimmune, Inc. to Report Q1, 2022 Results on May 12, 2022

Insufficient new directors

Altimmune's New Avatar As A Liver Disease Player

Altimmune Announces Initiation of 48-Week Phase 2 Momentum Trial of Pemvidutide in Obesity

Price target decreased to US$26.43

Consensus revenue estimates fall by 77%

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind